MNK Mallinckrodt plc

1.79
+0.09  (+5%)
Previous Close 1.7
Open 1.8
Price To Book 0.08
Market Cap 150,731,432
Shares 84,207,504
Volume 4,623,736
Short Ratio 5.31
Av. Daily Volume 8,229,194
Stock charts supplied by TradingView

NewsSee all news

  1. Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19 Infection and Associated Lung Complications

    -- Study to investigate antiviral activity and improvement in oxygenation and pulmonary arterial pressure in patients suffering from COVID-19 -- STAINES-UPON-THAMES, United Kingdom and GARDEN GROVE, Calif., April 1,

  2. Mallinckrodt Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)

    STAINES-UPON-THAMES, United Kingdom, March 17, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced the completion of its rolling submission of a New Drug Application

  3. Mallinckrodt Confirms Court Decision in Lawsuit Against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) and Provides Update Related to Global Opioid Settlement and Present Financing Activities

    STAINES-UPON-THAMES, United Kingdom, March 16, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today confirmed that its subsidiary, Mallinckrodt ARD LLC, received a decision from the

  4. Mallinckrodt Evaluates the Potential Role for Inhaled Nitric Oxide to Treat COVID-19 Associated Lung Complications, Engages with Scientific, Governmental and Regulatory Agencies

    STAINES-UPON-THAMES, United Kingdom, March 12, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today commented that it is currently evaluating the limited published evidence

  5. Mallinckrodt Provides Update on Proposed Global Opioid Settlement

    STAINES-UPON-THAMES, United Kingdom, March 11, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") today announced that New York State Attorney General Letitia James has

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Completion of NDA filing announced March 17, 2020.
Terlipressin
Hepatorenal syndrome (HRS) Type 1
CRL issued August 22, 2018.
Stannsoporfin
Jaundice
Phase 3 enrolment to stop following interim analysis February 20, 2019.
UVADEX (methoxsalen) and Therakos
Acute Graft Versus Host Disease
Approved April 30, 2015.
RAPLIXA
Hemostasis
BLA rolling submission has commenced - April 6, 2020.
StrataGraft skin tissue
Deep partial thickness severe burns - skin defects
Phase 3 trial did not show a statistically significant separation from placebo.
VTS-270
Niemann-Pick Disease
CRL issued December 12, 2018.
MNK-812
Pain
Phase 3 data released May 7, 2019 did not meet primary endpoint.
CPP-1X/sulindac
Familial Adenomatous Polyposis (FAP)
Phase 2 trial discontinued due to safety concerns - July 16, 2019.
H.P. Acthar Gel
Amyotrophic Lateral Sclerosis
Phase 2 commencement of dosing announced August 12, 2019.
MNK-6106
Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE)

Latest News

  1. Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19 Infection and Associated Lung Complications

    -- Study to investigate antiviral activity and improvement in oxygenation and pulmonary arterial pressure in patients suffering from COVID-19 -- STAINES-UPON-THAMES, United Kingdom and GARDEN GROVE, Calif., April 1,

  2. Mallinckrodt Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)

    STAINES-UPON-THAMES, United Kingdom, March 17, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced the completion of its rolling submission of a New Drug Application

  3. Mallinckrodt Confirms Court Decision in Lawsuit Against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) and Provides Update Related to Global Opioid Settlement and Present Financing Activities

    STAINES-UPON-THAMES, United Kingdom, March 16, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today confirmed that its subsidiary, Mallinckrodt ARD LLC, received a decision from the

  4. Mallinckrodt Evaluates the Potential Role for Inhaled Nitric Oxide to Treat COVID-19 Associated Lung Complications, Engages with Scientific, Governmental and Regulatory Agencies

    STAINES-UPON-THAMES, United Kingdom, March 12, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today commented that it is currently evaluating the limited published evidence

  5. Mallinckrodt Provides Update on Proposed Global Opioid Settlement

    STAINES-UPON-THAMES, United Kingdom, March 11, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") today announced that New York State Attorney General Letitia James has

  6. Data on Acthar® Gel (Repository Corticotropin Injection) Therapy in Immunoglobulin A Nephropathy (IgAN) Published in Kidney International Reports

    STAINES-UPON-THAMES, United Kingdom, March 5, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced publication of findings from a prospective, open-label pilot study to

  7. Mallinckrodt Announces Publication of New Data on Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis, Systemic Lupus Erythematosus and Dermatomyositis/Polymyositis Published in Open Access Rheumatology: Research and Reviews

    STAINES-UPON-THAMES, United Kingdom, March 4, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced findings from a retrospective medical record analysis to assess practice

  8. Mallinckrodt Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)

    STAINES-UPON-THAMES, United Kingdom, March 2, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced it initiated the rolling submission of a New Drug Application (NDA) to

  9. Mallinckrodt to Present New Data from two Studies on Acthar® Gel (Repository Corticotropin Injection) Therapy in Multiple Sclerosis (MS) Relapse at Fifth Annual ACTRIMS Forum 2020

    STAINES-UPON-THAMES, United Kingdom, Feb. 27, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, announced today that it will present new data from two studies of Acthar® Gel

  10. Mallinckrodt plc Reports Strong Fourth Quarter and 2019 Results

    STAINES-UPON-THAMES, United Kingdom, Feb. 25, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today reported results for the three months and fiscal year ended Dec. 27, 2019. Unless

  11. Mallinckrodt Announces Agreement in Principle for Global Opioid Settlement and Associated Debt Refinancing Activities

    STAINES-UPON-THAMES, United Kingdom, Feb. 25, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company") today announced that the Company and its specialty generics-focused

  12. Mallinckrodt to Report Earnings Results for Fourth Quarter and Fiscal 2019

    STAINES-UPON-THAMES, United Kingdom, Feb. 14, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, announced today that it will report fourth quarter and fiscal 2019 earnings results for

  13. Mallinckrodt Recognized as one of the "2020 Best Places to Work for LGBTQ Equality"

    STAINES-UPON-THAMES, United Kingdom, Jan. 30, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced that the company received the distinguished honor of "Best Places to

  14. Mallinckrodt to Present at the 38th Annual J.P. Morgan Healthcare Conference

    STAINES-UPON-THAMES, United Kingdom, Dec. 23, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, announced today that Mark Trudeau, President and Chief Executive Officer, and other

  15. First Patient Enrolled in Mallinckrodt Phase 4 Trial of Acthar® Gel (Repository Corticotropin Injection) for Severe Keratitis

    STAINES-UPON-THAMES, United Kingdom, Dec. 16, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4,

  16. Mallinckrodt Announces Plans to Update Its Incentive Compensation Clawback Policy and Create Opioid Report

    STAINES-UPON-THAMES, United Kingdom, Dec. 10, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced plans to update Mallinckrodt's Incentive Compensation Clawback

  17. Mallinckrodt Presents Data on a Novel Predictive Model to Identify Infants at Risk for Infantile Spasms (IS) at the 2019 Annual Meeting of the American Epilepsy Society (AES)

    STAINES-UPON-THAMES, United Kingdom, Dec. 7, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced findings on the use of a novel predictive model designed to more

  18. Mallinckrodt plc Announces Final Results of Exchange Transactions

    STAINES-UPON-THAMES, United Kingdom, Dec. 5, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:  MNK) today announced (1) the final results of the previously announced offers by its wholly owned subsidiaries, Mallinckrodt

  19. Mallinckrodt Moves Date and Time of Its Fireside Chat at Piper Jaffray Annual Healthcare Conference

    STAINES-UPON-THAMES, United Kingdom, Dec. 2, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, announced today that the Company now will present at the Piper Jaffray Annual Healthcare

  20. Data on Acthar® Gel (Repository Corticotropin Injection) Therapy in Symptomatic Sarcoidosis Published in Therapeutic Advances in Respiratory Disease

    STAINES-UPON-THAMES, United Kingdom, Nov. 26, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced findings from a large retrospective study of Acthar® Gel (repository

  21. Mallinckrodt plc Announces Early Results of Exchange Transactions

    STAINES-UPON-THAMES, United Kingdom, Nov. 19, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:  MNK) today announced (1) the early results of the previously announced offers by its wholly owned subsidiaries, Mallinckrodt

  22. Mallinckrodt to Present at Piper Jaffray Annual Healthcare Conference

    STAINES-UPON-THAMES, United Kingdom, Nov. 19, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, will present on Tuesday, Dec. 3, 2019, at the Piper Jaffray Annual Healthcare Conference

  23. Mallinckrodt Announces New Clinical Data Evaluating Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting

    STAINES-UPON-THAMES, United Kingdom, Nov. 12, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced data on patient-reported outcomes (PROs) showing Acthar® Gel (repository

  24. Mallinckrodt Presents Positive Phase 3 Results from its CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019

    STAINES-UPON-THAMES, United Kingdom, Nov. 11, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced results from its pivotal Phase 3 CONFIRM study to assess the efficacy

  25. Mallinckrodt to Present at Jefferies London Healthcare Conference

    STAINES-UPON-THAMES, United Kingdom, Nov. 8, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, will present at the Jefferies London Healthcare Conference in London on Wednesday, Nov.

  26. Mallinckrodt Announces Data Publication on the Treatment Effectiveness of Acthar® Gel (Repository Corticotropin Injection) for Resolution of Multiple Sclerosis Relapse in a U.S. Health Plan Population

    STAINES-UPON-THAMES, United Kingdom, Nov. 7, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced the publication of "Treatment Effectiveness for Resolution of

  27. Mallinckrodt plc Announces Exchange Offers and Consent Solicitations

    STAINES-UPON-THAMES, United Kingdom, Nov. 5, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:  MNK) today announced the commencement of private offers (each, an "Exchange Offer" and, collectively, the "Exchange

  28. Mallinckrodt plc Reports Earnings and Pipeline Advancements for the Third Quarter 2019 and Raises Adjusted Diluted Earnings Per Share Guidance Range for 2019

    STAINES-UPON-THAMES, United Kingdom, Nov. 5, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today reported results for the three months ended September 27, 2019. Unless otherwise

  29. Mallinckrodt Completes Sale of BioVectra Inc. for up to $250 Million

    STAINES-UPON-THAMES, United Kingdom, Nov. 4, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced it has completed the sale of its wholly owned subsidiary BioVectra Inc.

  30. Mallinckrodt Announces UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (CTCL) in Adults

    STAINES-UPON-THAMES, United Kingdom, Oct. 31, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced that UVADEX® (methoxsalen) has received regulatory approval in Australia

  31. Mallinckrodt Raises Awareness of Critical Role Respiratory Therapists Play in Patient Care During Respiratory Care Week

    STAINES-UPON-THAMES, United Kingdom, Oct. 21, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, is proud to celebrate Respiratory Care Week (October 20-26, 2019), and honor the role of

  32. Mallinckrodt to Present Results from its Pivotal Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019

    STAINES-UPON-THAMES, United Kingdom, Oct. 21, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced it will present results from its pivotal Phase 3 CONFIRM study in a

  33. Mallinckrodt to Report Earnings Results for Third Quarter 2019

    STAINES-UPON-THAMES, United Kingdom, Oct. 9, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, announced today that it will report third quarter 2019 earnings results for the period

  34. Mallinckrodt Announces Positive Top-Line Findings from its Observational Registry Assessing Relapse Recovery in Multiple Sclerosis Relapse Patients Treated with Acthar® Gel (Repository Corticotropin Injection)

    STAINES-UPON-THAMES, United Kingdom, Oct. 1, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced positive top-line findings from its observational registry to assess

  35. Mallinckrodt Finalizes Settlement to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit

    STAINES-UPON-THAMES, United Kingdom, Sept. 30, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), along with its wholly owned subsidiaries Mallinckrodt LLC and SpecGx LLC, today announced that it has executed a definitive

  36. Mallinckrodt Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of StrataGraft® Regenerative Tissue in Patients with Deep Partial-thickness Thermal Burns

    STAINES-UPON-THAMES, United Kingdom, Sept. 23, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced positive top-line results from its pivotal Phase 3 clinical trial

  37. Mallinckrodt to Present at Cantor Global Healthcare Conference

    STAINES-UPON-THAMES, United Kingdom, Sept. 20, 2019 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE:MNK), a global biopharmaceutical company, will present at the Cantor Global Healthcare Conference at the

  38. Mallinckrodt Analysis Suggests Acthar® Gel (Repository Corticotropin Injection) May be a Cost-Effective Option Compared to Other Late-Line, Adult Treatments for Multiple Sclerosis Relapse

    STAINES-UPON-THAMES, United Kingdom, Sept. 13, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced findings from a retrospective analysis of Acthar® Gel (repository

  39. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE:MNK) of the September 24,

  40. Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million

    STAINES-UPON-THAMES, United Kingdom and MIAMI, Sept. 10, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today announced it has entered into a definitive agreement to sell its wholly

  41. S&P Dow Jones Indices Announces Nine Companies Set to Join S&P MidCap 400; Ten Companies to Join S&P SmallCap 600

    NEW YORK, Sept. 6, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriately represents its market

  42. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm

    New York, New York--(Newsfile Corp. - September 6, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company") of the

  43. Mallinckrodt Announces Settlement in Principle to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit

    STAINES-UPON-THAMES, United Kingdom, Sept. 6, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), along with its wholly owned subsidiaries Mallinckrodt LLC and SpecGx LLC, today announced that it has reached a settlement

  44. ROSEN, A TOP RANKED LAW FIRM, Reminds Mallinckrodt plc Investors of Important September 24th Deadline in Securities Class Action – MNK

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mallinckrodt plc (NYSE:MNK) from February 28, 2018 through July 16, 2019,

  45. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE:MNK) and certain of its officers.   The

  46. SHAREHOLDER ALERT: RBGLY MNK PS EVH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the

  47. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE:MNK) of the September 24,

  48. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of RBGLY, NGHC, MNK and EVH

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the

  49. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm

    New York, New York--(Newsfile Corp. - September 3, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc (NYSE:MNK) ("Mallinckrodt" or the "Company") of the

  50. Mallinckrodt Announces Completion of Previously Disclosed Settlement Agreement with U.S. Department of Justice on Legacy Questcor Sales and Marketing Activities

    STAINES-UPON-THAMES, United Kingdom, Sept. 3, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a global biopharmaceutical company, today reported the company has finalized a previously disclosed agreement with the U.S.

  51. CLASS ACTION UPDATE for VNTR, RBGLY, MNK and VAL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested

  52. Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Mallinckrodt plc – MNK

    NEW YORK, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Mallinckrodt plc (NYSE:MNK) from February 28, 2018

  53. CLASS ACTION UPDATE for OMCL, MNK, PS and TWOU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in

  54. Zhang Investor Law Reminds Investors of Sept. 24 Deadline in Securities Class Action Lawsuit Against Mallinckrodt plc – MNK

    NEW YORK, Aug. 26, 2019 (GLOBE NEWSWIRE) -- New York, N.Y., August 26, 2019. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Mallinckrodt plc (NYSE:MNK)

  55. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline - MNK

    NEW YORK, Aug. 24, 2019 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE:  MNK) and certain of its officers. 

  56. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline - MNK

    NEW YORK, Aug. 24, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE:  MNK) and certain of its